Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Hamilton Research LLC

Neither a doctor nor a teaching hospital

Research payments

$1,377,242

213 payments

Through program year 2025, Hamilton Research LLC is reported as receiving $1,377,242 in research payments, across 213 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $175,171 47
2024 Research $330,671 34
2023 Research $68,304 17
2022 Research $279,145 21
2021 Research $113,667 25
2020 Research $273,124 38
2019 Research $137,159 31

Breakdown

Who paid Research payments · program years 2019–2025
  1. Janssen Research & Development, LLC $423,358 48 payments
  2. AbbVie, Inc. $412,560 81 payments
  3. Ucb SA $198,483 14 payments
  4. Amgen Inc. $139,836 7 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $129,464 7 payments
  6. Hoffmann-La Roche Limited $36,965 22 payments
  7. Pfizer Inc. $17,841 7 payments
  8. Boehringer Ingelheim International GmbH $10,978 9 payments
  9. UCB Biosciences Inc. $6,925 1 payment
  10. Boehringer Ingelheim Pharma GmbH & Co.KG $833 17 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines $205,760 10 payments
  2. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis $180,502 20 payments
  3. A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis $176,006 12 payments
  4. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf $158,839 15 payments
  5. BI 730357 PoCC and dose ranging in Psoriasis $79,076 3 payments
  6. M15-997 $68,356 20 payments
  7. Efficacy/Safety study of Apremilast in subjects with Mild-to-moderate Plaque Psoriasis (PSOR-022) $67,886 1 payment
  8. A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis $56,886 5 payments
  9. BI 730357 Psoriasis Long Term Extension $50,388 4 payments
  10. A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) $44,804 20 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record